ReVacc Scientific C50J18 | VSV-Pseudovirus_SARS-CoV-2 Omicron Strain BQ.1.1 Spike with luciferase reporter

品名：VSV-Pseudovirus_SARS-CoV-2 Omicron Strain BQ.1.1 Spike with luciferase reporter

货号：C50J18

品牌：ReVacc Scientific

规格：200 μl; 1000 μl

产品描述

Organism：SARS-Related Coronavirus 2 (virus caused COVID-19), Omicron BQ.1.1 variant.

This pseudotyped virus uses recombinant vesicular stomatitis virus (rVSV) to carry spike protein of SARS-CoV-2 (GenBank: MN908947) with multiple mutations initially identified in variant of Omicron BQ.1.1, including: T19I, LPP24-26del, A27S, HV69-70del, G142D, V213G, G339D, R346T, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The spike protein has a 18-aa cytoplasmic tail truncation for optimal infection. As pseudovirus infectivity of rVSV without its original G is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices. Infection of cells with this pseudotyped virus carrying luciferase reporter results in high level luciferase activity. See our titration result showing that the starting 2-fold diluted pseudovirus generates signal ~ 100,000-foldhigher than uninfected control (cell alone as background in blue). We also evaluated the neutralizing activity of one own S2-specific antibody RV6, one commercial antibody LY-CoV1404 (bebtelovimab) and two published antibodies: COVA1-16, CB6 by using this pseudotyped virus. The results showed that both COVA1-16 and CB6 antibodies showed abolished neutralizing activity against this variant, compared with neutralization against WT strain (Cat # P14N41). Bebtelovimab lost the majority of neutralization, consistent with CDC statement that BQ.1.1 is likely to be resistant to bebtelovimab. See figure